US2022042095A1PendingUtilityA1

Methods and compositions for monitoring and enhancing early embryo development

Assignee: WISCONSIN ALUMNI RES FOUNDPriority: Jan 15, 2013Filed: Oct 26, 2021Published: Feb 10, 2022
Est. expiryJan 15, 2033(~6.5 yrs left)· nominal 20-yr term from priority
Inventors:Hasan Khatib
C12Q 2600/124C12Q 2600/158C12Q 1/6876C12N 15/1135C12N 2310/14
72
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Method for determining developmental fate of early embryos comprises measuring the expression level of a gene selected from the group consisting of CDKIV1C, IGF2R, MAGEL2, MKRN3, NAP1L5, NDN, PEG3, PHLDA2, TSSC4, and UBE3A genes. Also disclosed is a method for improving pregnancy rate, wherein early embryos whose expression level of the MKRN3, NDN, PEG3, PHLDA2, TSSC4, or UBE3A gene is not increased, or the expression level of the CDKIV1C, IGF2R, MAGEL2, or NAP1L5 gene is not decreased, are selected for planting into a suitable uterus for further development. Also disclosed are methods for increasing the likelihood of an early embryo to develop successfully into full-term pregnancy, wherein a suitable amount of siRNA corresponding to the PHLDA2 gene is injected into a fertilized egg which is in turn cultured further and planted into a suitable uterus.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of selecting an embryo for planting into a uterus for further development, the method comprising i) obtaining a supply of embryos, and growing the embryos to a stage ready for planting into a uterus; ii) obtaining a cell from a pre-planting embryo; iii) determining the expression level in the cell of at least a gene selected from the group consisting of CDK1V1C, IGF2R, MAGEL2, MKRN3, NAP1L5, NDN, PEG3, PHLDA2, TSSC4, and UBE3A, and iv) planting the embryo into a suitable uterus if it does not show an increased expression level of the MKRN3, NDN, PEG3, PHLDA2, TSSC4, or UBE3A gene, or does not show a decreased expression level of the CDK1V1C, IGF2R, MAGEL2, or NAP1L5 gene. 
     
     
         2 . The method according to  claim 1 , wherein the embryo is a bovine embryo. 
     
     
         3 . The method according to  claim 2 , wherein the embryo from which a cell is extracted is not more than 8 days post fertilization. 
     
     
         4 . The method according to  claim 1 , wherein the embryo is in an embryonic developmental stage not later than a morula stage, or before the blastocyst stage, wherein there is no differentiation among the cells. 
     
     
         5 . The method according to  claim 3 , wherein the embryo is in an embryonic developmental stage before hatching and is ready for planting. 
     
     
         6 . The method according to  claim 3 , wherein the embryo has developed to comprise not more than about 32 cells. 
     
     
         7 . The method according to  claim 6 , wherein the embryo has developed to comprise not more than about 150 cells. 
     
     
         8 . The method according to  claim 1 , wherein the gene expression level is determined by real time qRT-PCR. 
     
     
         9 . The method according to  claim 1 , wherein the gene expression level is determined by real time qRT-PCR on mRNA extracted from the single cell. 
     
     
         10 . An in vitro fertilization method for breeding animal, the method comprising obtaining embryos via an in vitro fertilization procedure, selecting a suitable embryo according to  claim 1 , and planting into a suitable uterus to allow further development of embryos that do not show an increased expression level of the MKRN3, NDN, PEG3, PHLDA2, TSSC4, or UBE3A gene, or embryos that do not show a decreased expression level of the CDK1V1C, IGF2R, MAGEL2, or NAP1L5 gene. 
     
     
         11 . A method for selectively animal breeding using a multiple ovulation and embryo transfer procedure (MOET), the method comprising superovulating a female animal, collecting eggs from said superovulated female, in vitro fertilizing said eggs and allow the fertilized eggs to develop into INF embryos, selecting embryos according to  claim 1 , and planting into a uterus only embryos that do not show an increased expression level of the MKRN3, NDN, PEGS, PHLDA2, TSSC4, or UBE3A gene, or embryos that do not show a decreased expression level of the CDK1V1C, IGF2R, MAGEL2, or NAP1L5 gene.

Join the waitlist — get patent alerts

Track US2022042095A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.